ProCE Banner Activity

CME

MedicalMinute: Expert Answers to Key Questions in HER2 Testing in Metastatic Breast Cancer

Multimedia
This short activity provides expert insight into questions frequently asked by clinicians surrounding HER2 testing in metastatic breast cancer.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: December 10, 2020

Expiration: December 09, 2021

No longer available for credit.

Share

Faculty

Kimberly Allison

Kimberly Allison, MD

Professor of Pathology
Stanford University School of Medicine
Stanford, California

Mark D. Pegram

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Michael F. Press

Michael F. Press, MD, PhD

Harold E. Lee Chair in Cancer Research
Professor of Pathology
Department of Pathology
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Target Audience

This program is intended for oncologists, pathologists, and other healthcare providers who care for patients with breast, gastrointestinal, and lung cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review evidence-based guidelines and expert recommendations for assessing HER2, HER3, and TROP2 in the metastatic setting for breast, gastrointestinal, and lung cancers
  • Implement best practices for HER2, HER3, and TROP2 diagnostic testing and interpretation to guide integration of the latest targeted therapies into individualized treatment plans

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Mark D. Pegram, MD, has disclosed that he has received consulting fees from AstraZeneca, Daiichi Sankyo, Roche/Genentech, and Seattle Genetics.

Faculty Disclosure

Primary Author

Kimberly Allison, MD

Professor of Pathology
Stanford University School of Medicine
Stanford, California

Kimberly H. Allison, MD, has no relevant conflicts of interest to disclose..

Michael F. Press, MD, PhD

Harold E. Lee Chair in Cancer Research
Professor of Pathology
Department of Pathology
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California

Michael F. Press, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Biocartis, Lilly, Merck, Novartis, Puma, and Zymework; has received funds for research support from Cepheid, Lilly, Novartis, Puma, and Zymeworks; and holds private equity in TORL Biotherapeutics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 10, 2020, through December 09, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners to utilize diagnostics to guide treatment of various HER2-, HER3-, and TROP2-altered cancers in the metastatic setting, including breast, gastrointestinal, and lung.